Webinar: Safety of paclitaxel devices—What does the evidence say?


Jos van den Berg (Lugano, Switzerland), Antonio Micari (Bergamo, Italy) and Marianne Brodmann (Graz, Austria) sit down after a specially convened US FDA panel reviewed paclitaxel device data, with recommendations still to come. The physicians discuss the safety of paclitaxel devices and examine what the evidence says.

Micari presented a patient-level analysis from the IN.PACT randomised controlled trials to state that they have collectively shown there is no drug-related mortality signal and suggests that study design and conduct might be responsible for the “transient” mortality signal. He also looks at the long-term effectiveness of paclitaxel devices to state that the IN.PACT DCB (Medtronic) provides a vast improvement over plain balloon angioplasty, and shows “durable treatment benefit”.

Brodmann, meanwhile, outlines evidence from real world data sources – such as Medicare, OPTUM and VQI – which has indicated that there is “no difference in mid-term or long-term survival between patients treated with drug-coated or non drug-coated devices”.

Summing up, van den Berg states that several methods of investigation have demonstrated the absence of a dose relationship to mortality. “What we need to do now,” he says, is to “perform well-conducted real world comparative studies that are followed up for a sufficient duration”.

This webinar was filmed by SparkBio. Medtronic sponsored its distribution in association with Vascular News and Interventional News.


Please enter your comment!
Please enter your name here